Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Oral Single Doses of NNC0113-6856 in Healthy Male Participants

NCT05521256 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05521256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05521256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Oral Single Doses of NNC0113-6856 in Healthy Male Participants
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
August 26, 2022
Completion date
March 27, 2023
Enrollment
70 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, type 2 diabetes